Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Marie-Justine Paillard"'
Autor:
Chloé Drozd, Elsa Curtit, Quentin Jacquinot, Charlène Marquine, Laura Mansi, Loïc Chaigneau, Erion Dobi, Julien Viot, Guillaume Meynard, Marie-Justine Paillard, Morgan Goujon, Pauline Roux, Dewi Vernerey, Valérie Gillet, Hubert Bourdin, Silvio Galli, Nathalie Meneveau, Fabienne Mougin
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background Up to 70% of breast cancer patients report symptoms of insomnia during and after treatment. Despite the ubiquity of insomnia symptoms, they are under-screened, under-diagnosed and poorly managed in breast cancer patients. Sleep me
Externí odkaz:
https://doaj.org/article/5473dfa5db4749b08b82dda664fb277d
Autor:
Zohair Selmani, Chloé Molimard, Alexis Overs, Fernando Bazan, Loic Chaigneau, Erion Dobi, Nathalie Meneveau, Laura Mansi, Marie-Justine Paillard, Guillaume Meynard, Julien Viot, Marie-Paule Algros, Christophe Borg, Jean-Paul Feugeas, Xavier Pivot, Jean-Luc Prétet, Elsa Curtit
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract Breast cancers expressing high levels of Ki67 are associated with poor outcomes. Oncotype DX test was designed for ER+/HER2− early-stage breast cancers to help adjuvant chemotherapy decision by providing a Recurrent Score (RS). RS measures
Externí odkaz:
https://doaj.org/article/fb403b3f72cf4ec7a11eabb6e2d69679
Autor:
Quentin Jacquinot, Nathalie Meneveau, Antoine Falcoz, Malika Bouhaddi, Pauline Roux, Bruno Degano, Marion Chatot, Elsa Curtit, Laura Mansi, Marie-Justine Paillard, Fernando Bazan, Loïc Chaigneau, Erion Dobi, Guillaume Meynard, Dewi Vernerey, Xavier Pivot, Fabienne Mougin
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
BackgroundTrastuzumab is used, alone or in conjunction with standard chemotherapy, to treat HER2-positive breast cancer (BC). Although it improves cancer outcomes, trastuzumab. can lead to cardiotoxicity. Physical exercise is a safe and effective sup
Externí odkaz:
https://doaj.org/article/b99f6aa41f744bdf96b74aa0e763ad8d
Autor:
Guillaume Mouillet, Marie-Justine Paillard, Tristan Maurina, Dewi Vernerey, Thierry Nguyen Tan Hon, Hamadi Almotlak, Ulrich Stein, Fabien Calcagno, Diane Berthod, Elise Robert, Aurelia Meurisse, Antoine Thiery-Vuillemin
Publikováno v:
Trials, Vol 19, Iss 1, Pp 1-9 (2018)
Abstract Background Sunitinib is a tyrosine kinase inhibitor approved in the first-line metastatic renal cell carcinoma (MRCC) setting at the dose of 50 mg daily for 4 weeks followed by a pause of 2 weeks. Due to toxicity, this standard schedule (50
Externí odkaz:
https://doaj.org/article/c2f4c7276ffa44faa478a7ca6bf2d755
Autor:
Christophe Borg, Stefano Kim, Marine Jary, Marie-Justine Paillard, Julie Henriques, Antonin Schmitt, Marion Jacquin, Bernard Royer, Dewi Vernerey, Martin Demarchi, Thierry Nguyen
Publikováno v:
British Journal of Clinical Pharmacology. 87:1327-1337
Aim Raltitrexed (RTX) is a thymidylate synthase inhibitor with large pharmacokinetics (PK) variability that can be administered in case of 5-fluorouracil (5FU) intolerance or dihydropyrimidine dehydrogenase deficiency. While it is a more potent thymi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf44d97b27083cf601677b6443d1b175
https://doi.org/10.1111/bcp.14519
https://doi.org/10.1111/bcp.14519
Autor:
Zohair Selmani, Chloé Molimard, Alexis Overs, Fernando Bazan, Loic Chaigneau, Erion Dobi, Nathalie Meneveau, Laura Mansi, Marie-Justine Paillard, Guillaume Meynard, Julien Viot, Marie-Paule Algros, Christophe Borg, Jean-Paul Feugeas, Xavier Pivot, Jean-Luc Prétet, Elsa Curtit
Breast cancers expressing high levels of Ki67 are associated with poor outcomes. Oncotype DX® test was designed for ER+/HER2- early-stage breast cancers to help adjuvant chemotherapy decision by providing a Recurrent Score® (RS®). RS® measures th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1067abffda23dae2694a335b0cc9c45
https://doi.org/10.21203/rs.3.rs-677106/v1
https://doi.org/10.21203/rs.3.rs-677106/v1
Autor:
Zohair Selmani, Chloé Molimard, Alexis Overs, Fernando Bazan, Loic Chaigneau, Erion Dobi, Nathalie Meneveau, Laura Mansi, Marie-Justine Paillard, Guillaume Meynard, Julien Viot, Marie-Paule Algros, Christophe Borg, Jean-Paul Feugeas, Xavier Pivot, Jean-Luc Prétet, Elsa Curtit
Publikováno v:
Scientific reports. 12(1)
Breast cancers expressing high levels of Ki67 are associated with poor outcomes. Oncotype DX test was designed for ER+/HER2− early-stage breast cancers to help adjuvant chemotherapy decision by providing a Recurrent Score (RS). RS measures the expr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c3f89f5172c0f289e75f94b19cd170a
https://pubmed.ncbi.nlm.nih.gov/35256657
https://pubmed.ncbi.nlm.nih.gov/35256657
Autor:
Noemie Gassian, Sophie Paget-Bailly, Oum El Kheir Djoumakh, Laura Mansi, Erion Dobi, Fernando Bazan, Elsa Curtit, Loic Chaigneau, Nathalie Meneveau, Marie-Justine Paillard, Zohair Selmani, Julien Viot, Christophe Borg, Guillaume Meynard
Publikováno v:
Journal of Clinical Oncology. 40:e13020-e13020
e13020 Background: Until 2020, in human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC), the two first lines of metastatic treatment were well defined but after, many options were possible, most often combining targete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c44aae3acf99917c2d558df250da916e
https://doi.org/10.1200/jco.2022.40.16_suppl.e13020
https://doi.org/10.1200/jco.2022.40.16_suppl.e13020
Autor:
Marie-Paule Algros, Jean-Luc Prétet, Laura Mansi, Christophe Borg, Jean-Paul Feugeas, Nathalie Meneveau, Zohair Selmani, Elsa Curtit, Chloé Molimard, Loic Chaigneau, Alexis Overs, Marie-Justine Paillard, Julien Viot, Fernando Bazan, Erion Dobi, Guillaume Meynard, Xavier Pivot
Background: Breast cancers expressing high levels of Ki67 are associated with poor outcomes. To provide individualized patient care, reliability of prognostic and predictive information deriving from Ki67 assessment is essential. Oncotype DX® test w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c28613e30f4910f45a01776fff80982
https://doi.org/10.21203/rs.3.rs-525965/v1
https://doi.org/10.21203/rs.3.rs-525965/v1
Autor:
Dewi Vernerey, Hamadi Almotlak, Ulrich Stein, Thierry Nguyen Tan Hon, Antoine Thiery-Vuillemin, Fabien Calcagno, Tristan Maurina, Marie-Justine Paillard, Elise Robert, Aurélia Meurisse, Guillaume Mouillet, Diane Berthod
Publikováno v:
Trials, Vol 19, Iss 1, Pp 1-9 (2018)
Trials
Trials
Background Sunitinib is a tyrosine kinase inhibitor approved in the first-line metastatic renal cell carcinoma (MRCC) setting at the dose of 50 mg daily for 4 weeks followed by a pause of 2 weeks. Due to toxicity, this standard schedule (50 mg daily
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b16320b3c887d9db074ca3c6ca59d03
http://link.springer.com/article/10.1186/s13063-018-2613-8
http://link.springer.com/article/10.1186/s13063-018-2613-8